Pharmacokinetic and Pharmacodynamic of Rocuronium

Pontificia Universidad Catolica de Chile10 enrolled

Overview

The purpose of this study is characterize the dose-effect relationship of rocuronium bromide at the adductor pollicis and masseter muscles using an pharmacokinetic-pharmacodynamic (PKPD) model. The hypothesis is that masseter muscle has a greater sensitivity to the neuromuscular blockers (rocuronium), faster onset and slower recovery profile than the adductor pollicis muscle.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Neuromuscular Blockade

Interventions

Rocuronium BromideDRUG

Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Scheduled for elective surgery under general anesthesia. Exclusion Criteria: * Pregnancy. * Body mass index (BMI) \>25 kg/m2. * Anticipated difficult airway. * Surgery associated with great volume loss. * Presence of any neuromuscular, hepatic, renal, cardiac or respiratory disease. * Previous history of neuromuscular blockade allergy, and/or administration of drugs known to interfere with neuromuscular blockade

Outcomes

Primary Outcomes

strength measuring 2 acceleromyograph. One Placed at the masseter muscle and the other one at the adductor pollicis muscle.

Time frame: 60 minutes

Measure blood concentrations after administration rocuronium

Time frame: 120 minutes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.